Advertisement
JNJ vs OGN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and OGN is a Hold.
JNJ's RSI Indicator ascends from oversold territory
The RSI Oscillator for JNJ moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 14 of the 30 cases the stock moved higher. This puts the odds of a move higher at 47%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 39 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 21 of 47 cases over the following month. The odds of a continued upward trend are 45%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
JNJ moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.482) is normal, around the industry mean (-2.799). P/E Ratio (30.219) is within average values for comparable stocks, (21.101). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.041) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Momentum Indicator for OGN turns negative, indicating new downward trend
OGN saw its Momentum Indicator move below the 0 level on October 23, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In 50 of the 73 cases, the stock moved further down in the following days. The odds of a decline are at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 54 cases where OGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for OGN turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 21 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
OGN broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a +0.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in 183 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 89 of 235 cases where OGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 38%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 40 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. OGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.589) is normal, around the industry mean (-2.799). P/E Ratio (17.405) is within average values for comparable stocks, (21.101). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.006) settles around the average of (0.041) among similar stocks. OGN's P/S Ratio (0.589) is slightly lower than the industry average of (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
JNJ | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | |
SMR RATING 1..100 | 37 | |
PRICE GROWTH RATING 1..100 | 44 | |
P/E GROWTH RATING 1..100 | 8 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| JNJ | OGN | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 47% | N/A |
| Stochastic ODDS (%) | 4 days ago 48% | 4 days ago 63% |
| Momentum ODDS (%) | 4 days ago 46% | 4 days ago 68% |
| MACD ODDS (%) | 4 days ago 45% | 4 days ago 60% |
| TrendWeek ODDS (%) | 4 days ago 47% | 4 days ago 71% |
| TrendMonth ODDS (%) | 4 days ago 45% | 4 days ago 55% |
| Advances ODDS (%) | 15 days ago 46% | 20 days ago 64% |
| Declines ODDS (%) | 22 days ago 40% | N/A |
| BollingerBands ODDS (%) | 4 days ago 31% | 4 days ago 65% |
| Aroon ODDS (%) | 4 days ago 38% | 4 days ago 38% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 2 FA rating(s) are green while OGN’s FA Score has 1 green FA rating(s).
- JNJ’s FA Score: 2 green, 3 red.
- OGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 4 TA indicator(s) are bullish while OGN’s TA Score has 2 bullish TA indicator(s).
- JNJ’s TA Score: 4 bullish, 6 bearish.
- OGN’s TA Score: 2 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +3.23% price change this week, while OGN (@Pharmaceuticals: Major) price change was -0.07% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.96%. For the same industry, the average monthly price growth was -4.99%, and the average quarterly price growth was +5.56%.
Reported Earning Dates
JNJ is expected to report earnings on Jan 26, 2027.
OGN is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.96% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement